The increased use of biosimilars within the US Oncology Network generated more than $6 million of savings in the Centers for Medicare & Medicaid Services’ Oncology Care Model (OCM) during the first half of 2020. Read More ›

Providers participating in the Centers for Medicare & Medicaid Services’ (CMS’) value-based payment (VBP) models may realize a reduction in financial risk via biosimilar substitution. Read More ›

On September 21, 2022, the Association for Accessible Medicines (AAM), the leading trade association for generic and biosimilar manufacturers, released its 2022 U.S. Generic & Biosimilar Medicines Savings Report highlighting the value of generic and biosimilar medicines. Read More ›

A survey of US physicians who prescribe biologics to their patients revealed that 92% were confident in the safety and efficacy of biosimilars, 89% would prescribe a biosimilar to a new patient, and 80% were comfortable initiating the switching of patients who are stable on their current biologic medication to a biosimilar. Read More ›

On May 23, 2022, the Association for Accessible Medicines (AAM) and its Biosimilars Council urged the Federal Trade Commission (FTC) to investigate the competitive impact of pharmacy benefit managers (PBMs) and their various abusive behaviors that undermine patient access to safe, affordable pharmaceutical care. Read More ›

Biosimilars provide more options for care at a lower cost for patients, but due to Medicare’s perverse incentives, many pharmacy benefit managers and health plans have been slow to prioritize biosimilars, leaving savings on the table. Read More ›

This past year, the COVID-19 pandemic continued to impact the practice of medicine and the dissemination of treatment advances presented in scientific forums. Read More ›

A real-world retrospective study (Canadian population) showed that patients with HER2-positive neoadjuvant early breast cancer treated with trastuzumab-dkst versus trastuzumab achieved similar pCR rates. Read More ›

The results of the cost-efficiency analysis within the Centers for Medicare & Medicaid Services Oncology Care Model indicate that switching from reference pegfilgrastim to pegfilgrastim-jmdb provided cost-savings that could potentially be reallocated to food and transportation support. Read More ›

Preliminary findings of this retrospective study indicate that treatment with bevacizumab reference product may be associated with a higher risk for hypertension and proteinuria, whereas treatment with bevacizumab biosimilars correlated with shorter onset of these adverse events. Read More ›

Page 1 of 8

Subscribe Today!

To sign up for our free e-Newsletter or print publications, please enter your contact information below.

I'd like to receive:

OPM e-Newsletter
OPM print publication